Objective:To investigate the clinical efficacy of levofloxacin combined with ambroxol in the treatment of elderly patients with chronic obstructive pulmonary disease(COPD)and pulmonary infection.Methods:A total of 80 ...Objective:To investigate the clinical efficacy of levofloxacin combined with ambroxol in the treatment of elderly patients with chronic obstructive pulmonary disease(COPD)and pulmonary infection.Methods:A total of 80 elderly COPD patients with pulmonary infection,treated between December 2022 and November 2023,were randomly divided into a control group and an observation group,with 40 cases in each group.The control group was treated with levofloxacin hydrochloride,while the observation group received ambroxol hydrochloride injection in addition to the treatment in the control group.Laboratory indices(white blood cell count,procalcitonin,C-reactive protein,and apolipoprotein E levels),imaging-based pulmonary lesion absorption time,hospital stay,and incidence of adverse reactions were compared between the two groups.Results:After treatment,the biochemical indices of the observation group were significantly lower than those of the control group,with highly significant differences(P<0.001).Compared to the control group,the imaging-based pulmonary lesion absorption time and hospital stay of the observation group were significantly shorter(P<0.001).Additionally,the incidence of adverse reactions in the observation group was significantly lower than in the control group(P<0.05).Conclusion:Levofloxacin combined with ambroxol demonstrates advantages in improving biochemical indices,shortening imaging-based pulmonary lesion absorption time and hospital stay,and reducing adverse reaction rates in elderly COPD patients with pulmonary infection.It holds significant clinical application value.展开更多
BACKGROUND Cyclophosphamide(CP)is a potent chemotherapeutic and immunosuppressant agent,but its hepatotoxicity remains a significant concern.Ambroxol(ABX)is a mucolytic agent with emerging beneficial effects against o...BACKGROUND Cyclophosphamide(CP)is a potent chemotherapeutic and immunosuppressant agent,but its hepatotoxicity remains a significant concern.Ambroxol(ABX)is a mucolytic agent with emerging beneficial effects against oxidative stress and inflammation.AIM To investigate the hepatoprotective effects of ABX against CP-induced liver injury,focusing on oxidative stress,inflammation,and the possible role of cytoglobin,thioredoxin reductase 1(TXNRD1)and high-mobility group box 1(HMGB1).METHODS ABX(20 mg/kg)was orally administered for 7 days,and the rats received a single injection of CP(100 mg/kg)on day 5.Blood and liver samples were collected for analyses,and the affinity of ABX towards cytoglobin,TXNRD1,and HMGB1 was evaluated using molecular docking.RESULTS CP administration significantly elevated alanine aminotransferase,aspartate aminotransferase,and alkaline phosphatase,reduced albumin,and caused multiple histopathological alterations in the liver.ABX effectively restored liver function biomarkers and attenuated histopathological alterations.CP-induced oxidative stress was evidenced by increased malondialdehyde and decreased glutathione and antioxidant enzyme activities,all of which were ameliorated by ABX.CP upregulated toll-like receptor 4(TLR-4),nuclear factor-kappaB(NF-κB)p65 and pro-inflammatory cytokines,while downregulating cytoglobin,TXNRD1 and HMGB1.ABX suppressed TLR-4/NF-κB signaling and pro-inflammatory cytokines,and upregulated cytoglobin,TXNRD1 and HMGB1.In silico molecular docking revealed the affinity of ABX to bind with cytoglobin,TXNRD1,and HMGB1.CONCLUSION ABX protects against CP hepatotoxicity by mitigating oxidative stress,suppressing TLR-4/NF-κB signaling,and upregulating cytoglobin,TXNRD1 and HMGB1.ABX showed binding affinity towards cytoglobin,TXNRD1 and HMGB1.These findings suggest that ABX has therapeutic potential in alleviating hepatotoxicity associated with CP treatment.展开更多
This study explores the clinical efficacy of budesonide combined with ambroxol inhalation therapy for neonatal pneumonia.A total of 68 neonatal pneumonia patients treated at Li County Hospital from January 2023 to Dec...This study explores the clinical efficacy of budesonide combined with ambroxol inhalation therapy for neonatal pneumonia.A total of 68 neonatal pneumonia patients treated at Li County Hospital from January 2023 to December 2024 were randomly divided into a monotherapy group and a combination group,with 34 patients in each.The monotherapy group received ambroxol inhalation therapy,while the combination group received budesonide inhalation therapy in addition to ambroxol.The recovery progress,blood gas analysis indicators,inflammatory response improvement,and overall clinical efficacy were compared between the two groups.Results showed that the combination group experienced a significantly shorter time for body temperature normalization(3.36±0.58 days vs.4.59±0.45 days),oxygen inhalation duration(4.89±0.57min vs.6.96±0.79min),disappearance of shortness of breath and cough(4.56±0.29 days vs.6.63±0.75 days),and resolution of lung wet rales(5.62±1.46 days vs.7.92±1.28 days)compared to the monotherapy group(P<0.05).Additionally,the total effective rate was significantly higher in the combination group(97.06%)than in the monotherapy group(73.52%)(P<0.05).Post-treatment,the combination group exhibited significantly better blood gas analysis and inflammatory response indicators(P<0.05).These findings suggest that budesonide combined with ambroxol inhalation therapy can effectively improve blood oxygen saturation,reduce inflammation,promote faster recovery,and enhance overall clinical efficacy,making it a reliable treatment option for neonatal pneumonia.展开更多
Objective:To explore the clinical effect of ambroxol hydrochloride combined with rehabilitation training on COPD and its effect on pulmonary function.Methods:92 patients with COPD from May 2017 to may 2019 were random...Objective:To explore the clinical effect of ambroxol hydrochloride combined with rehabilitation training on COPD and its effect on pulmonary function.Methods:92 patients with COPD from May 2017 to may 2019 were randomly divided into control group(n=46)and observation group(n=46).The control group was treated with oxygen inhalation,expectorant,antispasmodic,anti infection and so on.The observation group was treated with ambroxol hydrochloride combined with rehabilitation training on this basis.Blood gas,lung function and inflammatory factors were compared before and after treatment.Results:the levels of SaO2 and PaO2 in the two groups were significantly higher than those before treatment P There was significant difference between the two groups(P<0.05-0.01).Besides,the level of lung function related indexes in the observation group was significantly higher than that in the control group(P<0.05).Conclusion:ambroxol hydrochloride combined with rehabilitation training has a significant clinical effect on COPD,which can effectively improve the blood gas index and reduce the level of blood gas inflammatory factors,thus affecting the lung function of COPD patients.展开更多
Objective:To observe the mechanism of Tanreqing and ambroxol combined with Azithromy for the treatment of mycoplasma pneumonia in children and offer help to mycoplasma pneumonia treatment.Methods:86 cases of mycoplasm...Objective:To observe the mechanism of Tanreqing and ambroxol combined with Azithromy for the treatment of mycoplasma pneumonia in children and offer help to mycoplasma pneumonia treatment.Methods:86 cases of mycoplasma pneumonia patients in our hospital were selected and randomly divided into observation group and control group, each group were 43 cases. Control group was treated with conventional therapy, and observation group was treated with Tanreqing and ambroxol combined with Azithromy based on conventional therapy, the changes of lung function [V-T (Tidal volume)/kg, t-PTEF/t-E (time ratio of peak to peak), TEF25/PTEF (Instantaneous velocity of exhaling tidal volume 75% and Peak tidal expiratory flow ratio) and MTIF/MTEF (medium-term inspiratory flow rate and medium-term expiratory flow rate ratio)], cytokines (IL-2, IL-10, IL-6 and TNF-α) and the myocardial enzymes [LDH (lactate dehydrogenase), CK-MB (creatine kinase isoenzyme), CK (creatine kinase) and AST (glutamic-oxaloacetic transaminase)] were detected before and after treatment.Results: The comparison of lung function, cytokines and themyocardial enzymes in the two groups before treatment was not statistically significant (P>0.05). MTIF/MTEF, themyocardial enzymes (LDH, CK-MB, CK and AST) and cytokines (IL-10, IL-6 and TNF-α) in both groups after treatment significantly decreased compared with that before treatment (P<0.05);lung function (V-T/kg, t-PTEF/t-E, TEF25/PTEF), and IL-2 in both groups after treatment significantly increased compared with that before treatment (P<0.05). Lung function (V-T/kg, t-PTEF/t-E, TEF25/PTEF), and IL-2 in observation group after treatment increased more significantly than that in control group (P<0.05), and MTIF/MTEF, themyocardial enzymes (LDH, CK-MB, CK and AST) and cytokines (IL-10, IL-6 and TNF-α) decreased more significantly than that in control group (P<0.05).Conclusions:Tanreqing and ambroxol combined with Azithromy could improve lung function, cytokines and the myocardial enzymes in children with mycoplasma pneumonia, which has a very important clinical significance of the treatment to mycoplasma pneumonia.展开更多
Objective: To evaluate the systemic inflammatory and stress response in patients with COPD complicated by pulmonary infection after bronchoalveolar lavage with ambroxol hydrochloride. Methods: A total of 78 patients w...Objective: To evaluate the systemic inflammatory and stress response in patients with COPD complicated by pulmonary infection after bronchoalveolar lavage with ambroxol hydrochloride. Methods: A total of 78 patients with COPD complicated by acute pulmonary infection who were treated in the hospital between October 2015 and January 2017 were collected as research subjects and divided into control group (n=39) and study group (n=39) by random number table. Control group received routine treatment, and study group received the routine + bronchoalveolar lavage with ambroxol hydrochloride. The differences in serum levels of inflammatory factors and oxidative stress indexes were compared between the two groups before treatment and after 1 week of treatment. Results: There was no statistically significant difference in serum levels of inflammatory factors and oxidative stress indexes between the two groups before treatment. After 1 week of treatment, serum inflammatory factors IL-2, IL-6, IL-8, TNF- , CRP and PCT levels of study group were lower than those of control group;serum oxidation indexes MDA, MPO and AOPPs levels were lower than those of control group while anti-oxidation indexes SOD, T-AOC and GSH-Px levels were higher than those of control group. Conclusion: Bronchoalveolar lavage with ambroxol hydrochloride can significantly inhibit the systemic inflammatory and oxidative stress response and help control the disease in patients with COPD complicated by pulmonary infection.展开更多
Objective:To study the effect of bronchoscopic ambroxol lavage on inflammatory factors in lavage fluid of patients with bronchiectasis complicated by infection.Methods:100 patients with bronchiectasis complicated by i...Objective:To study the effect of bronchoscopic ambroxol lavage on inflammatory factors in lavage fluid of patients with bronchiectasis complicated by infection.Methods:100 patients with bronchiectasis complicated by infection who were treated in our hospital between May 2012 and January 2016 were divided into the control group (n=54) who received conventional treatment and the observation group (n=46) who received intravenous anti-infection combined with bronchoscopic ambroxol lavage after the therapies were reviewed. The contents of inflammatory factors, adhesion molecules and acute phase proteins in lavage fluid were compared between the two groups.Results: Before treatment, the differences in contents of inflammatory factors, adhesion molecules and acute phase proteins in lavage fluid were not statistically significant between two groups of patients. After treatment, inflammatory factors IL-4, IL-6, IL-10 and TNF-α contents in lavage fluid of observation group were lower than those of control group;adhesion molecules sICAM-1 and VCAM-1 contents in lavage fluid were lower than those of control group;acute phase proteins CRP, AAG, HPT and CER contents in lavage fluid were lower than those of control group.Conclusion:Bronchoscopic ambroxol lavage can reduce airway inflammation in patients with bronchiectasis complicated by infection.展开更多
Objective: to analyze the clinical treatment of elderly patients with chronic obstructive pulmonary disease and severe pneumonia, and to explore the therapeutic effect of high-dose ambroxol combined with moxifloxacin....Objective: to analyze the clinical treatment of elderly patients with chronic obstructive pulmonary disease and severe pneumonia, and to explore the therapeutic effect of high-dose ambroxol combined with moxifloxacin. Methods: a total of 80 samples of elderly patients with chronic obstructive pulmonary disease and severe pneumonia were selected and admitted from March 2021 to March 2022. The patients were divided into experimental group and control group with a sample size of 40 in each group. The two groups of therapeutic drugs are ambroxol and moxifloxacin, the difference lies in the dosage of ambroxol, the experimental group is a large dose, and the control group is a conventional dose. The pulmonary function, inflammatory reaction and quality of life of the two groups before and after treatment were compared. Results: after one weeks treatment, there were significant differences in pulmonary function and inflammatory indexes such as forced expiratory volume (FEV1), forced vital capacity (FVC), C-reactive protein (CRP) and procalcitonin (PCT) levels between the two groups in the first second. The values of the first two indexes in the test group were higher, while those of the second two indexes were lower. The data of the test group and the control group showed P < 0.05 through statistical software analysis. The professional scale was used to evaluate the quality of life of the patients, and it was found that there were significant differences between the two groups in terms of each index data. The scores of the experimental group were all better, and the results of the statistical software analysis of the data of the control group were all P < 0.05. Conclusion: in the treatment of elderly patients with chronic obstructive pulmonary disease and severe pneumonia, the use of high-dose ambroxol combined with moxifloxacin can better improve the patients lung function, reduce the inflammatory response, and thus effectively improve the quality of life of patients.展开更多
Objective: to study the specific curative effect of ambroxol hydrochloride combined with dexamethasone in the treatment of silicosis complicated with pulmonary infection. Methods: 70 patients with silicosis complicate...Objective: to study the specific curative effect of ambroxol hydrochloride combined with dexamethasone in the treatment of silicosis complicated with pulmonary infection. Methods: 70 patients with silicosis complicated with pulmonary infection were selected from the respiratory department of the hospital as the research object, and their basic data were investigated before entering the group to participate in the study, and they could not enter the group to participate in the experiment until they were confirmed to be correct. At the same time, according to the principle of randomness, 70 patients were randomly divided into a single group and a combined group with different treatment methods. The former group was treated with ambroxol hydrochloride, while the latter group was treated with dexamethasone combined with ambroxol hydrochloride. The therapeutic effects were compared. Results: after the treatment measures were taken, only 2 patients in the combined group were ineffective, whereas 7 patients in the single group were ineffective. the curative effect of the combined group was relatively inferior to that of the combined group. at the same time, the remission time of each clinical symptom of the patients in the combined group was also relatively superior to that of the single group (p < 0.05). Secondly, the lung function indexes of the two groups of patients after treatment were significantly improved as compared with those before treatment, and the improvement of the combined group was better (P < 0.05). Conclusion: the combined therapy of ambroxol hydrochloride and dexamethasone can achieve good therapeutic effect on silicosis complicated with pulmonary infection and control the infection quickly.展开更多
Objective: to observe the effect of ambroxol hydrochloride in the treatment of senile pneumonia. Methods: 74 cases of senile pneumonia in our department were selected, and the time period was set from March 2019 to Ma...Objective: to observe the effect of ambroxol hydrochloride in the treatment of senile pneumonia. Methods: 74 cases of senile pneumonia in our department were selected, and the time period was set from March 2019 to March 2021. The grouping methods were special group and normal group, and the treatment methods were respectively ambroxol hydrochloride and routine treatment. Results: the effective rate and satisfaction rate of the special group were higher than that of the general group (P < 0.05), and the results were different. Conclusion: ambroxol hydrochloride is effective in the treatment of senile pneumonia and can be promoted.展开更多
BACKGROUND Lower respiratory tract viral infections are a major cause of mortality in children under five years old,leading to hundreds of thousands of fatalities annually.The highest risk is observed in infants under...BACKGROUND Lower respiratory tract viral infections are a major cause of mortality in children under five years old,leading to hundreds of thousands of fatalities annually.The highest risk is observed in infants under one year old,underscoring the critical need for safe and effective antiviral protocols.CASE SUMMARY A 9-month-old infant suffered from severe bronchiolitis as manifested by high fever(39°C),decreased appetite,tachypnea,wheezing,and oxygen desaturation(SpO284%on room air)and was effectively managed at home using Kelleni’s protocol,which includes age-adjusted dose of nitazoxanide(60 mg twice daily),ibuprofen and azithromycin,complemented by selective antihistaminic,antitussive and mucolytic immunomodulatory treatment.The fever resolved,wheezing became more prominent but without respiratory distress,and oxygen saturation gradually increased to 92%by day 10.Nitazoxanide exerts broad antiviral and immunomodulatory effects by enhancing host interferon responses and inhibiting viral replication,potentially attenuating airway inflammation and accelerating resolution of bronchiolitis.The nitazoxanide dose(60 mg twice daily for five days)was carefully adjusted based on the developmental expression and activity of the uridine diphosphate-glucuronosyltransferase 1A1 enzyme,responsible for its metabolism,ensuring safe age-appropriate administration.The infant’s clinical status steadily improved,and by day 14 the infant achieved full recovery with normalization of oxygen saturation(96%on room air).No adverse events occurred,and follow-up at day 28 confirmed sustained recovery.CONCLUSION To the best of my knowledge,this report presents,for the first time globally,a potential of nitazoxanide within Kelleni’s protocol to early manage infants younger than one year suffering from severe lower respiratory tract viral infection at home.Selective antitussive treatment,using agents such as low dose benproperine,was employed to mitigate troublesome cough and improve patient comfort without compromising respiratory function.Additionally,alpha amylase was used to facilitate pulmonary secretion clearance.The protocol aims to reduce morbidity and mortality from viral lower respiratory tract infections in this vulnerable population.展开更多
文摘Objective:To investigate the clinical efficacy of levofloxacin combined with ambroxol in the treatment of elderly patients with chronic obstructive pulmonary disease(COPD)and pulmonary infection.Methods:A total of 80 elderly COPD patients with pulmonary infection,treated between December 2022 and November 2023,were randomly divided into a control group and an observation group,with 40 cases in each group.The control group was treated with levofloxacin hydrochloride,while the observation group received ambroxol hydrochloride injection in addition to the treatment in the control group.Laboratory indices(white blood cell count,procalcitonin,C-reactive protein,and apolipoprotein E levels),imaging-based pulmonary lesion absorption time,hospital stay,and incidence of adverse reactions were compared between the two groups.Results:After treatment,the biochemical indices of the observation group were significantly lower than those of the control group,with highly significant differences(P<0.001).Compared to the control group,the imaging-based pulmonary lesion absorption time and hospital stay of the observation group were significantly shorter(P<0.001).Additionally,the incidence of adverse reactions in the observation group was significantly lower than in the control group(P<0.05).Conclusion:Levofloxacin combined with ambroxol demonstrates advantages in improving biochemical indices,shortening imaging-based pulmonary lesion absorption time and hospital stay,and reducing adverse reaction rates in elderly COPD patients with pulmonary infection.It holds significant clinical application value.
基金Supported by Princess Nourah bint Abdulrahman University Researchers Supporting Project Number(PNURSP2025R381),Princess Nourah bint Abdulrahman University,Riyadh,Saudi Arabia.
文摘BACKGROUND Cyclophosphamide(CP)is a potent chemotherapeutic and immunosuppressant agent,but its hepatotoxicity remains a significant concern.Ambroxol(ABX)is a mucolytic agent with emerging beneficial effects against oxidative stress and inflammation.AIM To investigate the hepatoprotective effects of ABX against CP-induced liver injury,focusing on oxidative stress,inflammation,and the possible role of cytoglobin,thioredoxin reductase 1(TXNRD1)and high-mobility group box 1(HMGB1).METHODS ABX(20 mg/kg)was orally administered for 7 days,and the rats received a single injection of CP(100 mg/kg)on day 5.Blood and liver samples were collected for analyses,and the affinity of ABX towards cytoglobin,TXNRD1,and HMGB1 was evaluated using molecular docking.RESULTS CP administration significantly elevated alanine aminotransferase,aspartate aminotransferase,and alkaline phosphatase,reduced albumin,and caused multiple histopathological alterations in the liver.ABX effectively restored liver function biomarkers and attenuated histopathological alterations.CP-induced oxidative stress was evidenced by increased malondialdehyde and decreased glutathione and antioxidant enzyme activities,all of which were ameliorated by ABX.CP upregulated toll-like receptor 4(TLR-4),nuclear factor-kappaB(NF-κB)p65 and pro-inflammatory cytokines,while downregulating cytoglobin,TXNRD1 and HMGB1.ABX suppressed TLR-4/NF-κB signaling and pro-inflammatory cytokines,and upregulated cytoglobin,TXNRD1 and HMGB1.In silico molecular docking revealed the affinity of ABX to bind with cytoglobin,TXNRD1,and HMGB1.CONCLUSION ABX protects against CP hepatotoxicity by mitigating oxidative stress,suppressing TLR-4/NF-κB signaling,and upregulating cytoglobin,TXNRD1 and HMGB1.ABX showed binding affinity towards cytoglobin,TXNRD1 and HMGB1.These findings suggest that ABX has therapeutic potential in alleviating hepatotoxicity associated with CP treatment.
文摘This study explores the clinical efficacy of budesonide combined with ambroxol inhalation therapy for neonatal pneumonia.A total of 68 neonatal pneumonia patients treated at Li County Hospital from January 2023 to December 2024 were randomly divided into a monotherapy group and a combination group,with 34 patients in each.The monotherapy group received ambroxol inhalation therapy,while the combination group received budesonide inhalation therapy in addition to ambroxol.The recovery progress,blood gas analysis indicators,inflammatory response improvement,and overall clinical efficacy were compared between the two groups.Results showed that the combination group experienced a significantly shorter time for body temperature normalization(3.36±0.58 days vs.4.59±0.45 days),oxygen inhalation duration(4.89±0.57min vs.6.96±0.79min),disappearance of shortness of breath and cough(4.56±0.29 days vs.6.63±0.75 days),and resolution of lung wet rales(5.62±1.46 days vs.7.92±1.28 days)compared to the monotherapy group(P<0.05).Additionally,the total effective rate was significantly higher in the combination group(97.06%)than in the monotherapy group(73.52%)(P<0.05).Post-treatment,the combination group exhibited significantly better blood gas analysis and inflammatory response indicators(P<0.05).These findings suggest that budesonide combined with ambroxol inhalation therapy can effectively improve blood oxygen saturation,reduce inflammation,promote faster recovery,and enhance overall clinical efficacy,making it a reliable treatment option for neonatal pneumonia.
基金Capital medical development research fund (2017-3147)
文摘Objective:To explore the clinical effect of ambroxol hydrochloride combined with rehabilitation training on COPD and its effect on pulmonary function.Methods:92 patients with COPD from May 2017 to may 2019 were randomly divided into control group(n=46)and observation group(n=46).The control group was treated with oxygen inhalation,expectorant,antispasmodic,anti infection and so on.The observation group was treated with ambroxol hydrochloride combined with rehabilitation training on this basis.Blood gas,lung function and inflammatory factors were compared before and after treatment.Results:the levels of SaO2 and PaO2 in the two groups were significantly higher than those before treatment P There was significant difference between the two groups(P<0.05-0.01).Besides,the level of lung function related indexes in the observation group was significantly higher than that in the control group(P<0.05).Conclusion:ambroxol hydrochloride combined with rehabilitation training has a significant clinical effect on COPD,which can effectively improve the blood gas index and reduce the level of blood gas inflammatory factors,thus affecting the lung function of COPD patients.
文摘Objective:To observe the mechanism of Tanreqing and ambroxol combined with Azithromy for the treatment of mycoplasma pneumonia in children and offer help to mycoplasma pneumonia treatment.Methods:86 cases of mycoplasma pneumonia patients in our hospital were selected and randomly divided into observation group and control group, each group were 43 cases. Control group was treated with conventional therapy, and observation group was treated with Tanreqing and ambroxol combined with Azithromy based on conventional therapy, the changes of lung function [V-T (Tidal volume)/kg, t-PTEF/t-E (time ratio of peak to peak), TEF25/PTEF (Instantaneous velocity of exhaling tidal volume 75% and Peak tidal expiratory flow ratio) and MTIF/MTEF (medium-term inspiratory flow rate and medium-term expiratory flow rate ratio)], cytokines (IL-2, IL-10, IL-6 and TNF-α) and the myocardial enzymes [LDH (lactate dehydrogenase), CK-MB (creatine kinase isoenzyme), CK (creatine kinase) and AST (glutamic-oxaloacetic transaminase)] were detected before and after treatment.Results: The comparison of lung function, cytokines and themyocardial enzymes in the two groups before treatment was not statistically significant (P>0.05). MTIF/MTEF, themyocardial enzymes (LDH, CK-MB, CK and AST) and cytokines (IL-10, IL-6 and TNF-α) in both groups after treatment significantly decreased compared with that before treatment (P<0.05);lung function (V-T/kg, t-PTEF/t-E, TEF25/PTEF), and IL-2 in both groups after treatment significantly increased compared with that before treatment (P<0.05). Lung function (V-T/kg, t-PTEF/t-E, TEF25/PTEF), and IL-2 in observation group after treatment increased more significantly than that in control group (P<0.05), and MTIF/MTEF, themyocardial enzymes (LDH, CK-MB, CK and AST) and cytokines (IL-10, IL-6 and TNF-α) decreased more significantly than that in control group (P<0.05).Conclusions:Tanreqing and ambroxol combined with Azithromy could improve lung function, cytokines and the myocardial enzymes in children with mycoplasma pneumonia, which has a very important clinical significance of the treatment to mycoplasma pneumonia.
文摘Objective: To evaluate the systemic inflammatory and stress response in patients with COPD complicated by pulmonary infection after bronchoalveolar lavage with ambroxol hydrochloride. Methods: A total of 78 patients with COPD complicated by acute pulmonary infection who were treated in the hospital between October 2015 and January 2017 were collected as research subjects and divided into control group (n=39) and study group (n=39) by random number table. Control group received routine treatment, and study group received the routine + bronchoalveolar lavage with ambroxol hydrochloride. The differences in serum levels of inflammatory factors and oxidative stress indexes were compared between the two groups before treatment and after 1 week of treatment. Results: There was no statistically significant difference in serum levels of inflammatory factors and oxidative stress indexes between the two groups before treatment. After 1 week of treatment, serum inflammatory factors IL-2, IL-6, IL-8, TNF- , CRP and PCT levels of study group were lower than those of control group;serum oxidation indexes MDA, MPO and AOPPs levels were lower than those of control group while anti-oxidation indexes SOD, T-AOC and GSH-Px levels were higher than those of control group. Conclusion: Bronchoalveolar lavage with ambroxol hydrochloride can significantly inhibit the systemic inflammatory and oxidative stress response and help control the disease in patients with COPD complicated by pulmonary infection.
文摘Objective:To study the effect of bronchoscopic ambroxol lavage on inflammatory factors in lavage fluid of patients with bronchiectasis complicated by infection.Methods:100 patients with bronchiectasis complicated by infection who were treated in our hospital between May 2012 and January 2016 were divided into the control group (n=54) who received conventional treatment and the observation group (n=46) who received intravenous anti-infection combined with bronchoscopic ambroxol lavage after the therapies were reviewed. The contents of inflammatory factors, adhesion molecules and acute phase proteins in lavage fluid were compared between the two groups.Results: Before treatment, the differences in contents of inflammatory factors, adhesion molecules and acute phase proteins in lavage fluid were not statistically significant between two groups of patients. After treatment, inflammatory factors IL-4, IL-6, IL-10 and TNF-α contents in lavage fluid of observation group were lower than those of control group;adhesion molecules sICAM-1 and VCAM-1 contents in lavage fluid were lower than those of control group;acute phase proteins CRP, AAG, HPT and CER contents in lavage fluid were lower than those of control group.Conclusion:Bronchoscopic ambroxol lavage can reduce airway inflammation in patients with bronchiectasis complicated by infection.
文摘Objective: to analyze the clinical treatment of elderly patients with chronic obstructive pulmonary disease and severe pneumonia, and to explore the therapeutic effect of high-dose ambroxol combined with moxifloxacin. Methods: a total of 80 samples of elderly patients with chronic obstructive pulmonary disease and severe pneumonia were selected and admitted from March 2021 to March 2022. The patients were divided into experimental group and control group with a sample size of 40 in each group. The two groups of therapeutic drugs are ambroxol and moxifloxacin, the difference lies in the dosage of ambroxol, the experimental group is a large dose, and the control group is a conventional dose. The pulmonary function, inflammatory reaction and quality of life of the two groups before and after treatment were compared. Results: after one weeks treatment, there were significant differences in pulmonary function and inflammatory indexes such as forced expiratory volume (FEV1), forced vital capacity (FVC), C-reactive protein (CRP) and procalcitonin (PCT) levels between the two groups in the first second. The values of the first two indexes in the test group were higher, while those of the second two indexes were lower. The data of the test group and the control group showed P < 0.05 through statistical software analysis. The professional scale was used to evaluate the quality of life of the patients, and it was found that there were significant differences between the two groups in terms of each index data. The scores of the experimental group were all better, and the results of the statistical software analysis of the data of the control group were all P < 0.05. Conclusion: in the treatment of elderly patients with chronic obstructive pulmonary disease and severe pneumonia, the use of high-dose ambroxol combined with moxifloxacin can better improve the patients lung function, reduce the inflammatory response, and thus effectively improve the quality of life of patients.
文摘Objective: to study the specific curative effect of ambroxol hydrochloride combined with dexamethasone in the treatment of silicosis complicated with pulmonary infection. Methods: 70 patients with silicosis complicated with pulmonary infection were selected from the respiratory department of the hospital as the research object, and their basic data were investigated before entering the group to participate in the study, and they could not enter the group to participate in the experiment until they were confirmed to be correct. At the same time, according to the principle of randomness, 70 patients were randomly divided into a single group and a combined group with different treatment methods. The former group was treated with ambroxol hydrochloride, while the latter group was treated with dexamethasone combined with ambroxol hydrochloride. The therapeutic effects were compared. Results: after the treatment measures were taken, only 2 patients in the combined group were ineffective, whereas 7 patients in the single group were ineffective. the curative effect of the combined group was relatively inferior to that of the combined group. at the same time, the remission time of each clinical symptom of the patients in the combined group was also relatively superior to that of the single group (p < 0.05). Secondly, the lung function indexes of the two groups of patients after treatment were significantly improved as compared with those before treatment, and the improvement of the combined group was better (P < 0.05). Conclusion: the combined therapy of ambroxol hydrochloride and dexamethasone can achieve good therapeutic effect on silicosis complicated with pulmonary infection and control the infection quickly.
文摘Objective: to observe the effect of ambroxol hydrochloride in the treatment of senile pneumonia. Methods: 74 cases of senile pneumonia in our department were selected, and the time period was set from March 2019 to March 2021. The grouping methods were special group and normal group, and the treatment methods were respectively ambroxol hydrochloride and routine treatment. Results: the effective rate and satisfaction rate of the special group were higher than that of the general group (P < 0.05), and the results were different. Conclusion: ambroxol hydrochloride is effective in the treatment of senile pneumonia and can be promoted.
文摘BACKGROUND Lower respiratory tract viral infections are a major cause of mortality in children under five years old,leading to hundreds of thousands of fatalities annually.The highest risk is observed in infants under one year old,underscoring the critical need for safe and effective antiviral protocols.CASE SUMMARY A 9-month-old infant suffered from severe bronchiolitis as manifested by high fever(39°C),decreased appetite,tachypnea,wheezing,and oxygen desaturation(SpO284%on room air)and was effectively managed at home using Kelleni’s protocol,which includes age-adjusted dose of nitazoxanide(60 mg twice daily),ibuprofen and azithromycin,complemented by selective antihistaminic,antitussive and mucolytic immunomodulatory treatment.The fever resolved,wheezing became more prominent but without respiratory distress,and oxygen saturation gradually increased to 92%by day 10.Nitazoxanide exerts broad antiviral and immunomodulatory effects by enhancing host interferon responses and inhibiting viral replication,potentially attenuating airway inflammation and accelerating resolution of bronchiolitis.The nitazoxanide dose(60 mg twice daily for five days)was carefully adjusted based on the developmental expression and activity of the uridine diphosphate-glucuronosyltransferase 1A1 enzyme,responsible for its metabolism,ensuring safe age-appropriate administration.The infant’s clinical status steadily improved,and by day 14 the infant achieved full recovery with normalization of oxygen saturation(96%on room air).No adverse events occurred,and follow-up at day 28 confirmed sustained recovery.CONCLUSION To the best of my knowledge,this report presents,for the first time globally,a potential of nitazoxanide within Kelleni’s protocol to early manage infants younger than one year suffering from severe lower respiratory tract viral infection at home.Selective antitussive treatment,using agents such as low dose benproperine,was employed to mitigate troublesome cough and improve patient comfort without compromising respiratory function.Additionally,alpha amylase was used to facilitate pulmonary secretion clearance.The protocol aims to reduce morbidity and mortality from viral lower respiratory tract infections in this vulnerable population.
